Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A David Rodrigues

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Journal of Pharmaceutical Sciences|January 22, 2023
Translatability of in vitro Inhibition Potency to in vivo P-Glycoprotein Mediated Drug Interaction RiskSarah Lazzaro, Mark A West, Soraya Eatemadpour, et al.
Proteomics|December 1, 2023
Proteomic profiling of paired human liver homogenate and tissue derived extracellular vesiclesZivile Useckaite, Lauren A Newman, Ashley M Hopkins, et al.
Clinical Pharmacology and Therapeutics|September 22, 2020
Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 BiomarkersMikko Neuvonen, Päivi Hirvensalo, Aleksi Tornio, et al.
Chemical Research in Toxicology|May 18, 2011
Estimation of the extent of in vivo formation of a mutagenic aromatic amine from a potent thyromimetic compound: correlation of in vitro and in vivo findingsKamelia Behnia, Georgia Cornelius, Jian Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2018
In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus MonkeyAyşe Ufuk, Rachel E Kosa, Hongying Gao, et al.
Chemical Research in Toxicology|September 28, 2016
Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/CholestasisKimberly Lapham, Jonathan Novak, Lisa D Marroquin, et al.
Clinical Pharmacology and Therapeutics|April 1, 2021
Exploring the Use of Serum-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting PolypeptidesA David Rodrigues, Madelé van Dyk, Michael J Sorich, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 16, 2003
Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteersA David Rodrigues, Rita A Halpin, Leslie A Geer, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 9, 2005
Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkeyMagang Shou, Wei Lu, Prasad H Kari, et al.
Clinical Pharmacology and Therapeutics|March 31, 2022
Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe DrugDavid A Tess, Emi Kimoto, Amanda King-Ahmad, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Journal of Pharmaceutical Sciences|January 22, 2023
Translatability of in vitro Inhibition Potency to in vivo P-Glycoprotein Mediated Drug Interaction RiskSarah Lazzaro, Mark A West, Soraya Eatemadpour, et al.
Proteomics|December 1, 2023
Proteomic profiling of paired human liver homogenate and tissue derived extracellular vesiclesZivile Useckaite, Lauren A Newman, Ashley M Hopkins, et al.
Clinical Pharmacology and Therapeutics|September 22, 2020
Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 BiomarkersMikko Neuvonen, Päivi Hirvensalo, Aleksi Tornio, et al.
Chemical Research in Toxicology|May 18, 2011
Estimation of the extent of in vivo formation of a mutagenic aromatic amine from a potent thyromimetic compound: correlation of in vitro and in vivo findingsKamelia Behnia, Georgia Cornelius, Jian Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2018
In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus MonkeyAyşe Ufuk, Rachel E Kosa, Hongying Gao, et al.
Chemical Research in Toxicology|September 28, 2016
Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/CholestasisKimberly Lapham, Jonathan Novak, Lisa D Marroquin, et al.
Clinical Pharmacology and Therapeutics|April 1, 2021
Exploring the Use of Serum-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting PolypeptidesA David Rodrigues, Madelé van Dyk, Michael J Sorich, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 16, 2003
Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteersA David Rodrigues, Rita A Halpin, Leslie A Geer, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 9, 2005
Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkeyMagang Shou, Wei Lu, Prasad H Kari, et al.
Clinical Pharmacology and Therapeutics|March 31, 2022
Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe DrugDavid A Tess, Emi Kimoto, Amanda King-Ahmad, et al.
Pageof 14